OBJECTIVES:

The objective of the study was to test the efficacy, safety and tolerability of triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia (FRDA) patients in a clinical pilot study.

Read More: Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial